FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: Results of an exploratory one-yr multicenter study

Clinical Transplantation

Volumn 23, Issue 5, 2009, Pages 589-599

  Tedesco Silva, H ^a   Lorber, M I ^b   Foster, C E ^c   Sollinger, H W ^d   Mendez, R ^e   Carvalho, D B ^f   Shapiro, R ^g   Rajagopalan, P R ^h   Mayer, H ⁱ   Slade, J ⁱ   Kahan, B D ^j  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e National Institute of Transplantation Los Angeles   (United States)

^f HOSPITAL GERAL DE BONSUCESSO   (Brazil)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

more..

Author keywords

CNI free regimen; Delayed graft function; Everolimus; FTY720; Renal transplantation

Indexed keywords

CORTICOSTEROID; EVEROLIMUS; FINGOLIMOD; METHYLPREDNISOLONE;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; BRADYCARDIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DELAYED GRAFT FUNCTION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; GRAFT FAILURE; HEART RATE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG FUNCTION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTOPENIA; WOUND DEHISCENCE;

ADULT; DELAYED GRAFT FUNCTION; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROPYLENE GLYCOLS; PROSPECTIVE STUDIES; SIROLIMUS; SPHINGOSINE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70350191952     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01070.x     Document Type: Article

References (43)

1. Cecka JM. The UNOS Renal Transplant Registry. Clin Transplant 2002, 1.
2. Gonin JM. Maintenance immunosuppression: new agents and persistent dilemmas. Adv Ren Replace Ther 2000, 7:95.
3. Matas AJ, Humar A, Gillingham KJ. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002, 62:704.
4. Tejani A, Stablein DM, Donaldson L. Steady improvement in short-term graft survival of pediatric renal transplants: the NAPRTCS experience. Clinical Transplant 1999, 95.
5. Ziolkowski J, Paczek L, Senatorski G. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003, 35:2307.
6. Pilmore HL, Dittmer ID. Calcineurin inhibitor nephrotoxicity: reduction in dose results in marked improvement in renal function in patients with coexisting chronic allograft nephropathy. Clin Transplant 2002, 16:191.
7. Ojo AO, Wolfe RA, Held PJ. Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997, 63:968.
8. de Mattos AM, Olyaei AJ, Bennett WM. Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis 2000, 35:333.
9. Cravedi P, Codreanu I, Satta A. Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer?. Nephron Clin Pract 2005, 101:c65.
10. Brinkmann V, Lynch KR. FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Curr Opin Immunol 2002, 14:569.
11. Mandala S, Hajdu R, Bergstrom J. Alteration of lymphocyte trafficking by sphingosine 1-phosphate receptor agonists. Science 2002, 296:346.
12. Brinkmann V, Davies MD, Heise CE. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002, 277:21453.
13. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004, 92:913.
14. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 (S1P1) in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004, 4:1019.
15. Yanagawa Y, Sugahara K, Kataoka H. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats: II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J Immunol 1998, 160:5493.
16. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000, 164:5761.
17. Lorber M, Mulgaonkar S, Butt KM. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-yr randomized, multicenter, phase III study. Transplantation 2005, 80:244.
18. Vitko S, Margreiter R, Weimar W. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004, 78:1532.
19. Kahan BD, Kaplan B, Lorber MI, Winkler M, Cambon N, Boger RS. RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. Transplantation 2001, 71:1400.
20. Eisen HJ, Tuzcu EM, Dorent R. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003, 349:847.
21. Schuler W, Sedrani R, Cottens S. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997, 64:36.
22. Stepkowski SM, Wang M-E, Qu X. Synergistic interaction of FTY720 with cyclosporine or sirolimus to prolong heart allograft survival. Transplant Proc 1998, 30:2214.
23. Hoshino Y, Yanagawa Y, Ohtsuki M. FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK506 in rat allograft models. Transplant Proc 1999, 31:1224.
24. Quesniaux FB, Menninger K, Kunkler A. The novel immunosuppressant FTY720 induces peripheral lymphodepletion of both T- and B-cells in cynomologus monkeys when given alone, with cyclosporine Neoral or with RAD. Transpl Immunol 2000, 8:177.
25. Nikolova Z, Hof A, Baumlin Y, Hof RP. Efficacy of SDZ RAD compared with CsA monotherapy and combined Rad/FTY720 treatment in a murine cardiac allotransplantation model. Transpl Immunol 2001, 9:43.
26. Schuurman HJ, Cottens S, Fuchs S. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997, 64:32.
27. Budde K, Schmouder RL, Brunkhorst R. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 2002, 13:1073.
28. Kahan BD, Karlix JL, Ferguson RM. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study. Transplantation 2003, 76:1079.
29. Tedesco-Silva H, Mourad G, Kahan BD. FTY720, a novel immunomodulator - efficacy and safety results from the first Phase 2a study in de novo renal transplantation. Transplantation 2005, 79:1553.
30. Mulgaonkar S, Tedesco H, Oppenheimer F. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose finding study. Am J Transplant 2006, 8:1848.
31. Researcher's Guide to the USRDS Database 1998, Bethesda, MD, The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31.
33. Racusen LC, Solez K, Colvin RB. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999, 55:713.
34. Tedesco-Silva H, Szakaly P, Shoker A. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation 2007, 84:885.
35. Salvadori M, Budde K, Charpentier B. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a one-year, randomized controlled trial in Europe and Australasia. Am J Transplant 2006, 6:2912.
36. Tedesco-Silva H, Pescovitz M, Cibrik D. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 2006, 82:1689.
37. Schiavelli R, Gaite L, Agost Carreno C. Use of enteric-coated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function. Transplant Proc 2006, 38:905.
38. Holdaas H, Bentdal O, Pfeffer P, Mjørnstedt L, Solbu D, Midtvedt K. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008, 22:366.
39. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch 1999, 438:642.
40. Mazurais D, Robert P, Gout B, Berrebi-Bertrand I, Laville MP, Calm T. Cell type-specific localization of human cardiac S1P receptors. J Histochem Cytochem 2002, 50:661.
41. Matloubian M, Lo C, Cinnamon G. Lymphocyte egress from thymus and peripheral lymphoid organs is sphingosine 1-phosphate receptor-1 dependent. Nature 2004, 427:355.
42. Kappos L, Antel J, Comi G. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124.
43. Lou HX, Vathsala A. Conversion from mycophenolate mofetil to azathioprine in high-risk renal allograft recipients on cyclosporine-based immunosuppression. Transplant Proc 2004, 36:2090.